CN1222304C - Medicine for treating turbid vitrious body and its prepn - Google Patents
Medicine for treating turbid vitrious body and its prepn Download PDFInfo
- Publication number
- CN1222304C CN1222304C CN 02135973 CN02135973A CN1222304C CN 1222304 C CN1222304 C CN 1222304C CN 02135973 CN02135973 CN 02135973 CN 02135973 A CN02135973 A CN 02135973A CN 1222304 C CN1222304 C CN 1222304C
- Authority
- CN
- China
- Prior art keywords
- medicine
- blood
- vitreous
- preparation
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses medicine for treating vitreous opacity and a preparation method thereof, which belongs to the technical field of manufacturing Chinese patent medicine. The present invention mainly solves the therapy problem of vitreous opacity caused by hemorrhage, inflammation and operations. The present invention comprises components of the following parts by weight: 10 to 20 of Danshen root, 10 to 20 of angelica, 10 to 20 of peach seeds, 10 to 20 of hemlock parsley, 25 to 30 of radix rehmanniae preparata, 8 to 15 of laminaria and 10 to 20 of liquoric root. In the preparation method, medicinal materials of which the impurities are removed are decocted in water, and decoction liquid is mixed and filtered; concentrated filter liquid is added with excipients to form Chinese patent medicine preparation. The medicine of the present invention belongs to a preparation type of dissolvable granules and can also be any other preparation types of pharmacy. Hygienics and pharmacology inspection shows that the medicine preparation has the advantages of stable quality, obvious therapeutic effect and no obvious side effect, and accords with pharmacopoeia standards; therefore, the present invention can be widely used for treating patients of vitreous opacity.
Description
Technical field
The present invention relates to Chinese patent medicine, specifically relate to a kind of Chinese medicine compound medicament of vitreous opacity and process of preparation thereof for the treatment of.
Background technology
Vitreous opacity is the common oculopathy of ophthalmology, but the severe patient blinding influences patient's study and work and life, causes great misery to patient, causes very big burden for society and family.In the tissue from the vitreous body vicinity, mostly be hemorrhage and the inflammation product, can cause the grievous injury of vision.Vitreous opacity is because systemic disease, wound, operation and tunica uvea inflammation cause.Systemic disease such as hypertension, high blood viscosity, diabetes, due to the retinal vein occlusion, periphlebitis of retina, diabetic retinopathy.Operation mostly is due to surgery of retinal detachment and the operation on vitreous.Inflammation mostly is choroidal inflammation of a variety of causes.Slight muddiness often can absorb voluntarily, but serious muddy case does not still have the absorption that effective medicine promotes vitreous opacity at present, and traditional in the past Western medicine is by treatments such as iodine preparation, hyaluronidases, and effect is undesirable.Operation on vitreous, apparatus expensive, complication is many, and is painful big, is difficult for popularizing.
Summary of the invention
One of purpose of the present invention is to provide a kind of Chinese medicine compound medicament for the treatment of vitreous opacity effectively; Another object of the present invention provides the method for this kind of preparation medicine.
About the understanding of the traditional Chinese medical science to vitreous opacity.No matter the vitreous opacity due to hemorrhage, the inflammation of ocular injury or retinopathy belongs to the traditional Chinese medical science " sudden blindness ", " look rave dusk vast " or categories such as " cloud and mist are invaded fine ".Think patient's deficiency of the liver and kindey, deficiency of both YIN and YANG, hyperactivity of fire caused by deficiency of YIN, bleeding due to blood-heat, qi depression to blood stasis, the vital essence consume, the order cervical carcinoma with cachexia is supported, eyes being lustreless and spiritless, seven emotions pent-up, with the passing of time stagnation of QI-blood loses and controls, and does not distinguish eyeball.Rule of treatment circulation of qi promoting is nourished blood, blood circulation promoting and blood stasis dispelling, removing blood stasis eliminating stagnation.
The component of medicine of the present invention is (weight portion): Radix Salviae Miltiorrhizae 10-20, Radix Angelicae Sinensis 10-20, Semen Persicae 10-20, Rhizoma Chuanxiong 10-20, Radix Rehmanniae Preparata 25-30, Thallus Laminariae (Thallus Eckloniae) 8-15, Radix Glycyrrhizae 10-20. gets medical material and removes impurity, decocts with water, collecting decoction filters, and filtrate is concentrated back adding excipient form Chinese formulated products.
This prescription is the monarch drug blood circulation promoting and blood stasis dispelling with the Radix Salviae Miltiorrhizae, and blood stasis dispelling is enriched blood.Nourish blood and regulate the flow of vital energy with the Radix Angelicae Sinensis removing blood stasis of invigorating blood circulation, Semen Persicae, Rhizoma Chuanxiong be blood stasis removing and clots absorbing but also to go into blood flat, blood-activating and qi-promoting not only, Xin Xiang wanders away, and mends and can lead to qi as the commander of blood, blood being the mother of qi, gas Lai Xuezai, blood is capable with gas, and the capable then blood of gas is capable, it is unable that the deficiency of vital energy then promotes blood flow, escape of blood from meridians is then excessive or the stasis of blood long-pending, and vitreous opacity is an impairment of both QI and blood, and the vim and vigour stasis of blood stagnates.So above 3 medicines bring out the best in each other with monarch drug as ministerial drug.Radix Rehmanniae Preparata, Thallus Laminariae (Thallus Eckloniae) are adjuvant drug, nourishing kidney yin, nourishing YIN and benefiting blood, the epiphora of enriching blood, eliminating stagnation blood stasis dispelling.Radix Glycyrrhizae is a messenger drug, coordinating the actions of various ingredients in a prescription.To reach the effect that phlegm reduction of blood circulation promoting, circulation of qi promoting nourish blood.
Each raw medicinal material all is kind of being included of Chinese Pharmacopoeia nineteen ninety-five version.
(1) monarch drug
Radix Salviae Miltiorrhizae: the nature and flavor hardship is slightly cold, and effect is blood circulation promoting and blood stasis dispelling, enriches blood, and should be used for the heat in blood stasis of blood and stagnate.Pharmacological research shows the effect of blood vessel slightly of diastole end.
(2) ministerial drug
Radix Angelicae Sinensis: the sweet arduous temperature of nature and flavor, effect is a tonifying blood and regulating menstruation, promoting blood circulation and stopping pain.Radix Angelicae Sinensis can removing blood stasis, and Radix Angelicae Sinensis can stop blooding, Radix Angelicae Sinensis energy and blood, and Xin Gan and be apt to wander away should be used for blood stasis and network.
Semen Persicae: nature and flavor hardship ' sweet ' is flat, and effect is the removing blood stasis blood stasis expelling, and it is flat to go into blood, and intestine moistening is suitable for card to control blood stasis congelation, and blood is dry not to be moistened..
Rhizoma Chuanxiong: property and flavor of peppery and warm, effect are blood-activating and qi-promoting, the wind pain relieving of loosing, and card is controlled vim and vigour and is stagnated.
(3) adjuvant drug
Radix Rehmanniae Preparata: the sweet tepor of nature and flavor.Effect is the tonification essence, nourishing the kidney and liver, nourishing YIN and benefiting blood.
Thallus Laminariae (Thallus Eckloniae): nature and flavor are salty-cold.Effect is the expectorant knot, the goiter of loosing, and containing iodine has the absorption dissipation role.
(4) messenger drug
Radix Glycyrrhizae: nature and flavor are sweet flat.Process and tepor current 12 warps.Effect is invigorating the spleen and replenishing QI, and lung moistening is eliminated the phlegm, heat-clearing and toxic substances removing, coordinating the actions of various ingredients in a prescription.Here mainly be that harmonizing drug is made priming usefulness.
The preparation method of the medicine of this kind treatment vitreous opacity comprises the following steps:
Take by weighing the following traditional Chinese medicines material and make raw material (weight portion): Radix Salviae Miltiorrhizae 10-16, Radix Angelicae Sinensis 12-16, Semen Persicae 12-16, Rhizoma Chuanxiong 10-15, Radix Rehmanniae Preparata 25-30, Thallus Laminariae (Thallus Eckloniae) 8-12, Radix Glycyrrhizae 10-15.Get medical material and remove impurity, decoct with water, collecting decoction filters, and filtrate is concentrated back adding excipient form Chinese formulated products.Pharmaceutical dosage form of the present invention is an electuary.Can also be the above other any dosage forms of pharmaceutics.
Its electuary preparation method is that above medical material is removed impurity, decocts with water 3 times, and each 1.5 hours, collecting decoction, filter,, get 1 part of extractum and add 3 parts of cane sugar powders filtrate about 1: 10 (90 ℃) extractum that is concentrated into relative density, 1.25 parts in dextrin adds an amount of ethanol and makes granule, dry.
The preparation method of its pill be get 1 part of above-mentioned extractum add flour or honey 3 parts, add an amount of ethanol and make pill.
The present invention selects authentic medicinal herbs to make with extra care through the modern Chinese medicine processing technique and forms.Has blood circulation promoting and blood stasis dispelling, the effect that circulation of qi promoting is nourished blood.Invigorating blood circulation to increase blood volume, the expansion peripheral vessel, and microcirculation improvement is removed the blood stasis of blood and is stagnated, and QI invigorating can make blood flow unobstructed, and circulation is accelerated, and helps tissue metabolism and muddy absorption.Show that through modern medicine study drug for invigorating blood circulation and eliminating stasis has the effect that increases peripheral blood flow and ease pain.Wherein the nourishing blood and promoting blood circulation medicine is obvious to the anticoagulant effect, and Radix Salviae Miltiorrhizae has the effect of diastole peripheral vessel, and removing blood stasis eliminating stagnation medicine has the effect that increases the peripheral blood flow.Thallus Laminariae (Thallus Eckloniae) contains the function of the helpful absorption of composition of iodine, and Radix Angelicae Sinensis has the effect that improves blood circulation.Multiple compound of phenolic acid is arranged in the Radix Salviae Miltiorrhizae solution, and anti peroxidation of lipid that this material tool is stronger and the effect of removing free radical have stronger platelet aggregation inhibitory activity, the effect of microcirculation improvement.Relevant zoopery shows that the Chinese medicine blood circulation promoting and blood stasis dispelling can make in the lagophthalmos and macrophage content increases, and phagocytosis strengthens.Thereby accelerate the removing of cell debris and inflammatory material.This product is the light brown granule, sweet, little hardship of distinguishing the flavor of.Cure mainly: because of inflammation, hemorrhage, the operation due to vitreous opacity.Check that through hygiology, pharmacology the said preparation steady quality meets standards of pharmacopoeia, safety coefficient is big, no obvious toxic-side effects.
For further specifying the curative effect of this medicine, further specify the present invention below by clinical practice.
One, clinical practice overview
1, diagnostic criteria: examination with slitlamp microscope, bleeder's vitreous body visible red cell or cerise clot, or the different taupe point-like of depth muddiness is arranged between the vitreous body fibrous framework, or there is rope strip shadow at the vitreous body rear portion.Visible dust shape, bulk or rope strip exudate in inflammation person's vitreous body, the vitreous body transparency reduces.Ophthalmofundoscopy, the criteria for classification according to the ophthalmology pandect is divided into level Four with vitreous opacity:
The I level, muddiness does not still influence fundus observation, or represents with " ± ".
The II level, the optical fundus reflection to red light is obvious, can dimly get a glimpse of optic disc and blood vessel, or represents with " ten ".
The III level be cannot see the optical fundus, and there is reflection to red light on the optical fundus, cannot see optical fundus blood vessel, or represents with " 10 ".
The IV level, lesser ring of Merkel be can't see reflection to red light, or represents with " 10 ".
2, physical data: the vitreous opacity patient that this medicament of clinical practice is for many years received treatment reaches more than thousand people, and it is evident in efficacy. wherein, accept year June in June, 1996 to 2002 diagnosis and treatment because of the vitreous opacity patient due to hemorrhage, inflammation and the operation, be divided into two groups at random, person's 90 examples that collection follows up a case by regular visits to the complete data, observation group's 45 examples wherein, matched group 45 examples.Include the standard of this research in: the vitreous opacity of vitreous hemorrhage (comprising blunt frustrating property ocular injury, the retinal vein occlusion, the vitreous hemorrhage of caused by hypertension) detachment of retina and vitrectomy postoperative, the convalescent vitreous opacity of choroiditis.Exclusion standard: the vitreous opacity that the vitreous hemorrhage due to the diabetic renal papillary necrosis, vitreous degeneration cause.
Observation group's 45 examples are simple eye morbidity 3 male 24 examples; Women's 21 examples.Age 21-74 year, average 49 years old, 31 examples more than 40 years old.Fall ill to 7-90 days begin treatment time average 18.3 days.Vitreous hemorrhage 19 examples; (ocular injury 13 examples, retinal detachment surgery 3 examples, the retinal vein occlusion 3 examples) uveitis 5 examples; Preceding 4 examples of retina reattachment, postoperative 14 examples, vitrectomy postoperative 3 examples.Muddy 10 examples of vitreous body IV level; Muddy 25 examples of III level; Muddy 10 examples of II level.Vision: light sensation person 5 examples; Manual at the moment person's 12 examples; Count the person's of finger 15 examples at the moment; 0.02-0.1 person's 6 examples; 0.2-0.5 person's 7 examples.
Matched group 45 examples, male's 27 examples, women's 18 examples; Age 30-70 year, average 45.6 years old.35 examples more than 40 years old.Fall ill to 7-80 days begin treatment time average 15.8 days.Vitreous hemorrhage 21 examples; Preceding 4 examples of (ocular injury 12 examples, the retinal vein occlusion 10 examples, retinal detachment surgery 3 examples) uveitis 8 examples 3 retina reattachments, postoperative 11 examples, vitrectomy postoperative 1 example.Muddy 9 examples of vitreous body IV level; Muddy 26 examples of III level; Muddy 10 examples of II level.Vision; Light sensation person 5 examples; Manual at the moment person's 13 examples; Count the person's of finger 13 examples at the moment; 0.02-0.1 person's 7 examples; 0.2-0.5 person's 7 examples.Two groups age, sex, the course of disease, and the degree of vitreous opacity aspect no difference of science of statistics.
3, Therapeutic Method: observation group, hemorrhage static back 1 all begin treatments.Oral the present invention each one bag every day secondary.As a week back state of an illness no change, can increase to every day three times, 1 month treatment time.Matched group prolonium iodide pin, 2ml, a day intramuscular injection was treated 1 month.
4, observed content and time: two groups of patients observe the degree of variation of patient's naked vision and slit lamp lower-glass body muddiness all in treating front and back promoting the circulation of blood routine, going out clotting time, routine urianlysis.Adopt venous blood mensuration hemorheology index on an empty stomach before and after respectively getting 30 patient treatments, liver function, color Doppler is measured the blood flow parameter of Zinn's artery (CRA), arteriae ciliares posteriores breves (PCA) simultaneously, uses the 5-10mHz high frequency probe, sampling volume is 1.5-3.0mm, and doppler angle is less than 15 degree; Sample point: CRA is 2-3mm behind the endosphere rear wall of optic nerve dark space, and PCA is 3-5mm place behind the other ball rear wall in dark space, the peak systolic flow velocity PSV of observation CRA and PCA, diastasis blood flow rate EDV, drag index (R1).Inspection is finished by same skilled operators.Before and after the part patient take pictures in the row optical fundus.1 month treatment time.
5, follow up a case by regular visits to the time: follow-up period 3-62 month, average 20.8 months. wherein follow up a case by regular visits to person's 28 examples more than 1 year.
6, curative effect mark Huaihe River: vision is a check criteria with the international standard visual acuity chart,
Produce effects: vision is risen to more than 0.2 by light sensation, is risen to more than 0.3 by index, rise more than 4 row by 0.1, or vitreous opacity by the IV level to the II level; By III to the I level; It is high-visible to return to the optical fundus by the II muddiness.
Effectively: vision rises to more than 0.04 by light sensation or vision rises more than two row, or vitreous opacity by the IV level to the III level, by III level II level;
Invalid: vision is constant or descend, and vitreous opacity is constant or increase the weight of.
7, instrument and equipment: color Doppler ultrasonography in diagnosis analytical system: ALTHD15000 type (U.S.'s product).
Hemorheology detector (place of production) MVIS one 2010 full-automatic blood flow analysis systems (Chongqing Tian Hai equipment research is produced).
Fundus camera (place of production).NICON50 type (Japan produces).
8, statistical method: this research adopts other t check of two sample difference in means and X 2 test that data are carried out statistical analysis, is the difference significance with P＜0.05.
Two, result:
1, two groups of curative effects and vitreous body contaminated product assimilation effect see Table 1.
Table 1 liang group curative effect is (example) relatively
| Observation group's matched group | Example several 45 45 | Produce effects 27 9 | Effective 14 20 | Invalid 4 16 | Obvious effective rate % 60 20 | Total effective rate % 91.1 64.4 |
x
2Value: 9.86P＜0.01
Can go out observation group from table 1 and be better than matched group, difference has the highly significant meaning between two groups.
2, the hemorheology change sees Table 2.
The comparison of hemorheology index before and after the table 2 liang group treatment (x ± s)
| Observation index | Matched group (n=30) | Observation group (n=30) | ||||||
| Before the treatment | After the treatment | The t value | P | Before the treatment | After the treatment | The t value | P | |
| Whole blood viscosity (height is cut) | 4.96±2.17 | ?4.34±1.15 | ?1.37 | ＞0.05 | ?4.95±2.26 | ?3.47±1.85 | ?2.79 | ＜0.001* |
| Whole blood viscosity (low cutting) | 8.37±2.98 | ?7.92±2.01 | ?0.68 | ＞0.05 | ?8.38±3.06 | ?6.68±2.57 | ?2.46 | ＜0.05* |
| Plasma viscosity (mpas) | 1.59±0.27 | ?1.50±0.10 | ?1.73 | ＞0.05 | ?1.56±0.20 | ?1.48±0.13 | ?3.50 | ＜0.001** |
| Fibrinogen (g/L) | 3.46±1.66 | ?3.44±1.41 | ?0.11 | ＞0.05 | ?3.52±1.86 | ?2.81±1.40 | ?2.84 | ＜0.01* |
Annotate: compare * P＜0.05 * * P＜0.01 after observation group treatment back and the treatment of control group
Observation group's treatment back whole blood viscosity, plasma viscosity, Fibrinogen all have obvious reduction before than treatment: relatively the whole blood viscosity height is cut before and after two groups of treatments, plasma viscosity and Fibrinogen difference has highly significant meaning (P＜0.01).Whole blood viscosity is low cuts difference significance meaning (P＜0.05).Above Notes of Key Data hemorheology changes with this drug effect closely related.
3, treat front and back liver function, routine blood test, routine urinalysis for two groups, going out clotting time does not have obvious change, and prompting the present invention influences liver function and the conventional nothing of hematuria.
4, Zinn's artery and PCA blood flow data relatively see Table 3, table 4 before and after two groups of treatments.
The comparison of Zinn's artery hemodynamic index before and after the table 3 liang group treatment (x ± s)
| Observation index | Matched group (n=30) | Observation group (n=30) | ||||||
| Before the treatment | After the treatment | The t value | P | Before the treatment | After the treatment | The t value | P | |
| PVS | ?9.78±2.97 | ?9.78±2.97 | ?0.62 | ＞0.05 | ?9.86±2.18 | ?11.98±3.35 | ?3.32 | ＜0.01** |
| EDV | ?3.08±1.02 | ?3.42±1.31 | ?1.13 | ＞0.05 | ?3.42±1.52 | ?4.09±1.45 | ?2.58 | ＜0.05* |
| RI | ?0.68±0.23 | ?0.75±0.31 | ?1.01 | ＞0.05 | ?0.70±0.23 | ?0.57±0.27 | ?2.16 | ＜0.05** |
Annotate: compare * * P＜0.01 * P＜0.05 after observation group treatment back and the treatment of control group.
The comparison of arteriae ciliares posteriores breves hemodynamic index before and after the table 4 liang group treatment (x ± s)
| Observation index | Matched group (n=30) | Observation group (n=30) | ||||||
| Before the treatment | After the treatment | The t value | P | Before the treatment | After the treatment | The t value | P | |
| PVS | ?8.65±2.76 | ?9.43±2.43 | ?1.44 | ＞0.05 | ?8.97±3.43 | ?11.07±2.62 | ?2.71 | ＜0.01* |
| EDV | ?2.57±1.65 | ?2.98±2.03 | ?0.85 | ＞0.05 | ?3.31±1.54 | ?4.23±1.96 | ?2.01 | ＜0.05* |
| RI | ?0.53±0.35 | ?0.62±0.29 | ?1.08 | ＞0.05 | ?0.59±0.31 | ?0.43±0.15 | ?2.53 | ＜0.05** |
Annotate: compare * * P＜0.01 * P＜0.05 after observation group treatment back and the treatment of control group.
The peak systolic blood flow rate (PSV) of Zinn's artery and PCA before and after observation group's treatment, blood flow rate diastasis (EDV) all increases, drag index (R1) reduces, and two groups of treatment back comparing differences have significance meaning P＜0.05 PSV to increase then the highly significant meaning.Illustrate that this medicine has the improvement effect to retina and choroidal microcirculation.
Untoward reaction: obvious adverse reaction is seen in the equal end of 45 routine patients by observation group.
Three, model case
The 1st routine Zhao, man, 57 years old, admission number 195861.Because of the unexpected anopia of left eye went into to be in hospital in 2 days.Admission examination: blood pressure 16/10Kpa, heart rate 70 times/minute, examination of eyes left eye light sensation, corneal transparency, preceding aqueous humor is clear, the posterior lens capsule muddiness, the block hematocele of red color visible in the vitreous body, it is reflective to can't see the optical fundus redness, is diagnosed as vitreous hemorrhage.Be vitreous opacity IV level.Lab testing liver function, blood glucose, to go out clotting time all normal, and the blood examination whole blood viscosity is higher than normally.Hemodynamics checks that PSV, the EDV of PCA and CRA reduce, RI raises, and gives mannitol 250ml, once a day, the hemostasis sheet treatment 12 days that makes eye bright, patient's vision is increased to FC/30cm.Still visible clot in the vitreous body, the latent show color in optical fundus is reflective, give the present invention and treat each one bag, every day three times, treat three days visible right eyes at the bottom of redness reflective, clot is moving spends increasing, vision is increased to 0.08.Continue treatment one all visions and return to 0.2, the optical fundus other lamellar of dim visible temporo top vein is hemorrhage, around it vitreous body bar rope tractive is arranged, and the back of leaving hospital continues to treat two weeks with the present invention, vision restoration to 0.3, and the vitreous body substantially transparent is I level vitreous opacity.Because of the posterior lens capsule muddiness, vision does not continue to recover, and hemodynamic parameter improves.
Visual deterioration is 5 days after 48 years old admission number 201745 right eye wound of the 2nd routine Zhang woman, admission examination right vision 0.02, corneal transparency, the anterior chamber is dark slightly, and the pupil medicine looses big, and posterior lens capsule is slightly muddy, visible clot in the vitreous body, visible optical fundus redness is reflective, is III level vitreous opacity.Give etamsylate after being admitted to hospital, the FUFANG DANSHEN ZHUSHEYE treatment, 10 days, vision was increased to 0.08, inactive former medicine gives the present invention one bag, every day three times, an oral week, vision restoration to 0.3, vitreous hemorrhage absorbs, organise thing deposition of optical fundus visible vessels, below, the back of leaving hospital continue with this medicine 10 days, the vitreous body below still can be changed according to circumstances, and is surplus all transparent, vision 0.6, the more preceding weight of crystalline capsule muddiness, the hemorheology mathematic(al) parameter reduces, and hemodynamic index improves.
The 3rd example, Ma Liji, woman, 23 years old.Admission number 203157, the Equatorial Guinean, the foreign student, shadow is 20 days before the right eye, and blurring of vision was admitted to hospital in 10 days.Admission examination: right vision 0.08, corneal transparency, KP are the Adeps caprae seu ovis shape, aqueous humor hot spot (+), the pupil circle, light reflex is blunt, and crystalline lens is transparent, vitreous opacity, red color visible is reflective, the ambitus, top is latent sees the speckle that oozes out of 2 3PD sizes, the vitreous body bar rope that its table organises, and vitreous opacity is the III level.Intraocular pressure 30mmHg is diagnosed as panuveitis, and the acute retinal necrosis syndrome is suspicious, the secondary glaucoma.Give 0.5 dead point day of ribavirin three times, prednisolone 80mg dead point was treated 7 days once a day, vision restoration to 0.3, conceal and see optical fundus blood vessel, macular area edema, and visible point-like necrosis region, hormone is decrescence measured, and treats 1.5 months visions and does not have obvious raising, and vitreous body still is an II level muddiness, leave hospital behind the inactive hormone, give the present invention one bag after leaving hospital merely, every day three times, treated 15 days, vision is extensive to 0.6, and vitreous body I level muddiness has pigment around the focus of retina top, the macular area edema alleviates, continued to take medicine 20 days, vision restoration to 0.8 corrects 1.0, vitreous body is transparent, the optical fundus is high-visible, and macular edema disappears, and pigment is arranged around the last focus.
The 4th example Xu certain, man, 45 years old, admission number 205020.Because of left eye below shadow, blurring of vision was admitted to hospital admission examination in 5 days: the big ceasma of vision 0.2 top retina 5PD.The top detachment of retina, macula lutea is got involved, and is admitted to hospital to give the scleral encircling operation cryocoagulation in back 3 days, because ceasma is big, condensation reaction is heavy in the art, first day patient's vision FC/30cm of postoperative, the visible clot of vitreous body and concentrated, pigment granule, the latent show color in optical fundus is reflective, gives etamsylate and hyaluronidase treatment 15 days, vision does not have raising, the optical fundus red color visible is reflective, and the three mirror contact lens inspection is latent sees that the top ceasma pricks ridge surrounding nethike embrane at ring and have hemorrhagely, is III level vitreous opacity.Give the present invention treatment, all rear vitreous bodies are II degree muddiness, conceal and see optical fundus blood vessel, and retina calms down, the upper aperture envelope, and two weeks of the present invention are continued in the back of leaving hospital, and it is transparent that vitreous body recovers, and the optical fundus is clear, the rectification 0.4 of correcting defects of vision.
Four, curative effect and experimental analysis
This group data shows, treat the back height with the present invention and cut the white former obvious reduction of whole blood viscosity, plasma viscosity and fiber dawn, illustrate that this medicine has strengthened erythrocyte deformability in the blood, reduced erythrocytic aggregation, good deformability makes erythrocyte flow through blood capillary easily, thereby has improved microcirculation.Owing to strengthened fibrinolytic and reduced fibrinous stable factor, promoted the process of haemolysis and fibrinolytic.About the hemodynamics change of the vitreous hemorrhage due to eyeball contusion and central retinal vein occlusion is observed, find that the former can cause the PSV attenuating of CRA, and the PSV of the latter's CRA, PCA is starkly lower than strong eye of patient and normal control group, and RI obviously increases.Uveitic patient is early stage, and RI reduces because inflammatory stimulus causes vasodilation, and convalescent period then raises.Regilb etc. to detachment of retina patient art before, the capable CDI of postoperative checks and finds, the Zinn's artery of detachment of retina eye and ophthalmic artery blood flow rate and the no significant difference of contrast eye before the art, postoperative first day, the mean blood flow velocity comparison of Zinn's artery is according to falling 35% now, one week of postoperative descends 50%, and ophthalmic artery does not have the significance change.We organize 60 routine vitreous opacity patient hemodynamics results to this and analyze, the present invention treats 30 examples, treatment back PCA PCA and Zinn's artery (CRA) systole peak flow velocity (PSV), blood flow rate diastasis (EDV) meansigma methods increases, drag index (R1) then reduces, with more variant significance meaning before the treatment, with comparison PVS after the treatment of control group, RI difference has the significance meaning, possible reason is by treatment of the present invention, strengthened macrophage to bib, hemosiderin, inflammatory cell, and pigment granule phagocytic activity, quickening is to the removing of harmful substance, the blood supply of choroidal artery bed is improved help flowing of blood, increase the retinal blood flow, and by adjusting the permeability of blood capillary, increase the opening of capillary bed and improve retinal microcirculation and the confession of local organization blood, simultaneously also quickened the drainage of metabolite, quickened the absorption of vitreous opacity, thereby retardance vitreous organization and PVR form.
In sum; this research is treated vitreous opacity from hemodynamics and hemorheology aspect to the present invention and is carried out more comprehensive and systematic observation; studies show that; the present invention can accelerate the absorption of vitreous opacity; effectively the protection visual function especially provides a kind of effective Therapeutic Method for postoperative vitreous opacity.
Attention: electuary of the present invention, since prescription, the sugar content height, sugariness is big, and the patient who is unsuitable for the diabetic retinopathy vitreous opacity uses.This type of patient, other dosage forms that can utilize the present invention to fill a prescription.
Specific embodiment
Example one: take off column weight amount proportion raw material component: Radix Salviae Miltiorrhizae 10, Radix Angelicae Sinensis 10, Semen Persicae 10, Rhizoma Chuanxiong 10, Radix Rehmanniae Preparata 25, Thallus Laminariae (Thallus Eckloniae) 8, Radix Glycyrrhizae 10.Above medical material is removed impurity, decoct with water 3 times, each 1.5 hours, collecting decoction filtered, and with filtrate about 1: 10 (90 ℃) extractum that is concentrated into relative density, got 1 part of extractum and added 3 parts of cane sugar powders, and 1.25 parts in dextrin adds an amount of ethanol and makes granule, dry.The 15g/ bag, six bags of every bags.Oral, every day three times, each one bag, warm boiled water, or follow the doctor's advice.Airtight, moistureproof, preserve under the room temperature.
Example two: take off column weight amount proportion raw material component: Radix Salviae Miltiorrhizae 20, Radix Angelicae Sinensis 20, Semen Persicae 20, Rhizoma Chuanxiong 20, Radix Rehmanniae Preparata 30, Thallus Laminariae (Thallus Eckloniae) 15, Radix Glycyrrhizae 20.Above medical material is removed impurity, decoct with water 3 times, each 1.5 hours, collecting decoction filtered, and with filtrate about 1: 10 (90 ℃) extractum that is concentrated into relative density, got 1 part of extractum and added 3 parts of cane sugar powders, and 1.25 parts in dextrin adds an amount of ethanol and makes granule, dry.The 15g/ bag, six bags of every bags.Oral, every day three times, each one bag, warm boiled water, or follow the doctor's advice.Airtight, moistureproof, preserve under the room temperature.
Example three: take off column weight amount proportion raw material component: Radix Salviae Miltiorrhizae 12, Radix Angelicae Sinensis 12, Semen Persicae 12, Rhizoma Chuanxiong 12, Radix Rehmanniae Preparata 27, Thallus Laminariae (Thallus Eckloniae) 9, Radix Glycyrrhizae 15.Above medical material is removed impurity, decoct with water 3 times, each 1.5 hours, collecting decoction filtered, and with filtrate about 1: 10 (90 ℃) extractum that is concentrated into relative density, got 1 part of extractum and added 3 parts of cane sugar powders, and 1.25 parts in dextrin adds an amount of ethanol and makes granule, dry.The 15g/ bag, six bags of every bags.Oral, every day three times, each one bag, warm boiled water, or follow the doctor's advice.Airtight, moistureproof, preserve under the room temperature.
Example four: take off column weight amount proportion raw material component: Radix Salviae Miltiorrhizae 15, Radix Angelicae Sinensis 15, Semen Persicae 15, Rhizoma Chuanxiong 15, Radix Rehmanniae Preparata 30, Thallus Laminariae (Thallus Eckloniae) 10, Radix Glycyrrhizae 15.Above medical material is removed impurity, decoct with water 3 times, each 1.5 hours, collecting decoction filtered, and filtrate is concentrated into relative density about 1: 10 (90 ℃)) extractum, add 3 parts of flour or honey, add an amount of ethanol and make ball.The 15g/ ball, oral, every day three times, each ball, warm boiled water, or follow the doctor's advice.Airtight, moistureproof, preserve under the room temperature.
Claims (5)
1, a kind of medicine for the treatment of vitreous opacity, the medical material that it is characterized in that taking off column weight amount proportioning are as raw material: Radix Salviae Miltiorrhizae 10-20, Radix Angelicae Sinensis 10-20, Semen Persicae 10-20, Rhizoma Chuanxiong 10-20, Radix Rehmanniae Preparata 25-30, Thallus Laminariae (Thallus Eckloniae) 8-15, Radix Glycyrrhizae 10-20, get above-mentioned medical material and remove impurity, decoct with water collecting decoction, filter, filtrate is concentrated back adding excipient form Chinese formulated products.
2, a kind of medicine for the treatment of vitreous opacity according to claim 1 is characterized in that described Chinese formulated products is a dissolved granule.
3, a kind of method for preparing the described medicine of claim 1 is characterized in that the Chinese crude drug that takes by weighing following weight proportion makes raw material: Radix Salviae Miltiorrhizae 10-20, Radix Angelicae Sinensis 10-20, Semen Persicae 10-20, Rhizoma Chuanxiong 10-20, Radix Rehmanniae Preparata 25-30, Thallus Laminariae (Thallus Eckloniae) 8-15, Radix Glycyrrhizae 10-20 removes impurity with above medical material, decoct with water 3 times, each 1.5 hours, collecting decoction filtered, filtrate is concentrated into about 1: 10 extractum of 90 ℃ of following relative densities, and the back adds excipient and forms Chinese formulated products.
4, method according to claim 3 is characterized in that getting 1 part of extractum and adds 3 parts of cane sugar powders, and 1.25 parts in dextrin adds an amount of ethanol and makes granule, dry.
5, method according to claim 3, it is characterized in that getting 1 part of extractum add flour or honey 3 parts, add an amount of ethanol and make pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135973 CN1222304C (en) | 2002-12-11 | 2002-12-11 | Medicine for treating turbid vitrious body and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135973 CN1222304C (en) | 2002-12-11 | 2002-12-11 | Medicine for treating turbid vitrious body and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1506080A CN1506080A (en) | 2004-06-23 |
| CN1222304C true CN1222304C (en) | 2005-10-12 |
Family
ID=34231580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02135973 Expired - Fee Related CN1222304C (en) | 2002-12-11 | 2002-12-11 | Medicine for treating turbid vitrious body and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1222304C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208663A (en) * | 2014-05-15 | 2014-12-17 | 陈才生 | Method for treating macular optic disc vascular diseases by introduction of iodine-enzyme-ligusticum wallichii drug ions |
-
2002
- 2002-12-11 CN CN 02135973 patent/CN1222304C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1506080A (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210169779A1 (en) | Ophthalmic drug preparation and uses thereof | |
| CN102600386A (en) | Chinese herba preparation for treating eye inflammation and preparation method of Chinese herba preparation | |
| CN104095982B (en) | A kind of natural plant extracts compound formulation and its production and use | |
| JP6663018B2 (en) | Chinese herbal composition for the treatment of diabetic retinopathy | |
| CN102058845A (en) | Medicinal composition for treating macular degeneration | |
| CN1222304C (en) | Medicine for treating turbid vitrious body and its prepn | |
| CN102512467A (en) | Ophthalmic preparation of panax notoginseng saponins and preparation method thereof | |
| CN112121104B (en) | Traditional Chinese medicine composition for relieving asthenopia and preventing and treating myopia | |
| CN107789430A (en) | A kind of application of Chinese medicine composition in preventing/treating macular degeneration disease medicine is prepared | |
| CN103705899B (en) | Pharmaceutical composition that a kind for the treatment of of diabetic retinopathy becomes and its production and use | |
| CN1037151C (en) | Blood pressure lowing plaster and its preparation | |
| CN104740334B (en) | It is a kind of to be used to prevent and treat Chinese medicine composition of cataract and preparation method thereof | |
| CN103251725B (en) | A kind of application of Chinese medicine composition in treatment keratitis medicine is prepared | |
| CN1123350C (en) | Chinese patent medicine (Tangweiping) for treating eyeground affection of diabetes | |
| CN103055112B (en) | Traditional Chinese medicine compound composition for treating uveitis | |
| CN106540170A (en) | A kind of Chinese medicine for treating the bleeding eye diseases such as macular degeneration, retinal vein obstruction | |
| CN1061251C (en) | Blood circulation promoting capsule for hemalopia | |
| CN104096153A (en) | Pharmaceutical composition containing multiple plant active ingredients and preparation method and application thereof | |
| CN113332366A (en) | Application of medical composition in preparing medicine for treating xerophthalmia | |
| CN104306579B (en) | A kind of Chinese medicine for treating deficiency of yin and stagnation of blood diabetic retinopathy and preparation method and application | |
| CN103006847B (en) | Eye drops for treating uveitis and preparation method thereof | |
| CN100500192C (en) | Medicine for treating eye vitreous hemorrhage and turbidity and its preparation method | |
| CN101249094A (en) | Use of synthetic vitamin B1 derivative for preparing ophthalmocace medicament | |
| CN104800465A (en) | Traditional Chinese medicine composition for treating stagnation of qi due to depression of liver type primary glaucoma | |
| CN104587139A (en) | Pharmaceutical composition for treating juvenile myopia and application of pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |